Patients treated for major depression are likely to obtain optimal benefit with the lower dose range of second-generation antidepressants, a large review of published and unpublished trial data has found.

The findings, published in Lancet Psychiatry, will have clinical implications for some pharmacological treatment guidelines, the researchers say.